Eledon Pharmaceuticals Inc. held its Annual Meeting of Stockholders on June 10, 2025. The stockholders approved the election of Keith A. Katkin, Allan D. Kirk, M.D., Ph.D., FACS, and John S. McBride as Class II Directors. An amendment to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares was approved. An amendment to the Certificate of Incorporation to provide exculpation for certain officers was also approved. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。